| Keyword | Abstracts |
Affected relative pairs | 45 |
Analysis of re-sequencing data | 6,9,12,13,23,24,25,26,27,28,30,31,32,33,35,36,38,113 |
Ascertainment | 145,182,208 |
Association | 7,14,18,20,22,23,26,29,32,35,36,37,39,40,44,46,47,50,52,54,59,60,61,62,67,74,79,85,87,94,101,102, 105,110,111,112,114,115,119,120,122,123,124,125,127,129,131,132,134,138,139,140,143,144,145, 147,148,150,154,159,163,181,182,186,187,188,189,192,194,196,198,199,205,207,210,212,214,217, |
Autoimmune disorders | 189,192,202,220 |
Bayesian analysis | 1,10,14,18,22,80,82,88,96,185,221,232,245 |
Bioinformatics | 25,33,57,64,77,84,89,92,93,97,118,135,151,184,215 |
Cancer | 27,42,84,86,97,99,133,155,157,166,174,175,177,186,191,209,219,223 |
Cardiovascular risk factors and hypertension | 29,62,83,130,153,160,171,180,181,187,208,237 |
Case-Control Studies | 1,3,10,20,28,30,34,37,43,54,68,69,70,75,98,108,117,118,119,128,136,146,147,177,194,205, |
Case-only design | 61,67,68,195 |
Causation | 170,182,241 |
Copy Number Variation | 39,40,41,42,43,44,45,46,47,136,195 |
Data mining | 4,21,60,63,77,81,228 |
Diabetes | 16,21,57,189,192,203,224 |
Familial aggregation and segregation analysis | 27,53,169,172,175,197,200,220 |
Family-based Association Studies | 31,48,72,96,123,152,154,156,157,159,162,163,165,168,169,178,179,193,204,212 |
Fine mapping | 13,18,32,33,80,106,156,163,195,207,211 |
Gene - environment interactions | 15,58,62,69,71,131,204 |
Gene expression arrays | 87,90,91,92,185 |
Gene expression patterns | 17,83,86,89,91,93,95 |
Gene-environment interaction | 7,14,16,51,57,65,66,67,68,70,73,85,95,97,143,144,191,200,209,223,233,243 |
Genetic Pathways | 52,76,78,79,82,83,84,85,91,139 |
Genome scan | 2,7,11,16,17,30,37,45,50,53,64,65,79,81,92,94,108,110,120,124,127,128,129,130,132, |
Genomic variation | 8,12,19,26,38,87,103,104,126,135,164,183,193,199 |
Haplotype analysis | 22,103,111,113,115,116,117,118,120,124,148,167,211 |
Heritability | 190,200,241 |
Heterogeneity, Homogeneity | 29,66,101,131,137,184,202,210,213 |
Late onset Disease | 166,194,210 |
Liability | 233 |
Linkage analysis | 99,153,155,158,161,166,171,172,174 |
Linkage and association | 24,69,73,157,160,170,180 |
Machine Learning Tools | 2,225 |
Markov Chain Monte Carlo methods | 8,52,107,121,237 |
Maximum likelihood methods | 112,176,246 |
Missing data, genotyping errors | 8,11,121,122,127,142,148,197,243 |
Multifactorial Diseases | 9,12,13,15,19,63,117,169,216,226,233,246 |
Multilocus analysis | 1,2,10,34,48,49,50,53,54,59,61,63,76,77,81,90,119,147,159,216,220,226,242,244,245 |
Multiple marker disequilibrium analysis | 107,115,121,150,229 |
Multivariate phenotypes | 9,21,141,152,162 |
Mutation analysis | 11,190 |
Pharmacogenetics | 35,82,125,183,239 |
Population stratification | 40,101,102,103,105,106,107,108,109,110,123,138,173,190,193,227 |
Quantitative trait analysis | 15,17,23,24,25,34,36,86,90,93,122,130,134,137,140,156,168,180,184,196,198,203,230,234 |
Sample size | 5,98,104,141,143,144,164,173,214 |
Single nucleotide polymorphism | 19,31,38,43,47,51,65,66,76,80,89,96,98,113,116,125,126,128,135,136,146,150,158,167, |
Transmission / disequilibrium test | 48,154,162,168,173 |